Gillian McGovern is an associate editor at Pharmacy Times®. She graduated from Rowan University in 2023 with a BA in Writing Arts and concentrations in Publishing & Writing for the Public, Technical & Professional Writing, and Creative Writing.
CDC Recommends International Travelers Receive MMR Vaccination 2 Weeks Prior to Travel
August 2nd 2024The CDC says that even if travel is less than 2 weeks away, unvaccinated individuals should still receive a dose of the measles, mumps, and rubella vaccine for protection against the disease.
Read More
Expert: Tau Oligomers Are a Culprit in the Spread of Alzheimer Disease Pathology
August 1st 2024Tara Spires-Jones, DPhil, FMedSci, discusses how oligomeric tau clumps inside brain synapses, pointing to indirect evidence that it may be progressing through the brain by jumping between connections.
Read More
Long-Acting Injectable Form of Cabotegravir Safe for HIV Prevention in Pregnant Cisgender Women
July 29th 2024An extension of a long-acting cabotegravir study shows safety prior to and during pregnancy in cisgender women, with full results being presented at the 2024 International AIDS Conference.
Read More
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
July 23rd 2024Following President Joe Biden’s decision to step down from re-election, VP Kamala Harris has stepped into the Democratic nominee position after support and endorsements from notable delegates and the president himself.
Read More
Study Finds 1 in 10 Pregnant Individuals Who Test Positive For COVID-19 Will Develop Long COVID
July 17th 2024The investigators note that the high prevalence of long COVID, including in pregnant individuals, emphasizes a need for health care professionals and patients to closely monitor symptoms.
Read More
Odronextamab Demonstrates Durable Responses in Patients With R/R FL, DLBCL in Ongoing Trial
July 2nd 2024The results are promising for patients with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma, and the trial is ongoing to assess the efficacy of odronextamab in other subtypes.
Read More